CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol ...
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, and the non-profit Sickle Cell 101, ...
Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Cell-Based Assay & High Content Screening Market 2025-2029 - Forecasts by User and Product, with Executive and Consultant Guides" has been added to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback